and Akoya Biosciences multiplex-immunohistochemistry diagnostic products for tissue analysis.
The companies have also agreed to market end-to-end workflow solutions for multiplex assays in the clinical research market.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the partnership, Agilent will integrate its Dako Omnis auto-staining instrument with Akoya鈥檚 imaging platform, PhenoImager HT, for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays.
This integration will create a single end-to-end commercial workflow that will include reagents, staining, imaging and analysis.
Together Agilent and Akoya will develop chromogenic and immunofluorescent multiplex assays, which will include spatial analysis for companies that develop precision therapeutics for cancer.
The new assays will help researchers and medical professionals meet patient selection requirements for new therapeutics as well as quickly advance their discoveries to clinical testing.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUsing multiplex imaging, spatial phenotyping provides the advantages of single-cell analysis while allowing the preservation of the spatial relationships between cells.
Agilent Diagnostic and Genomics Group president Sam Raha said: 鈥淲e are delighted to be partnering with Akoya to create industry-leading products and services for multiplex chromogenic and immunofluorescence tissue assays.
鈥淭his partnership enables an ecosystem that assists the development of novel precision cancer therapeutics and offers a streamlined workflow to our joint customers in the clinical research market to meet the needs of future clinical diagnostics.鈥�
The company stated that the collaboration aims to develop an end-to-end multiplex solution for biomarker clinical research that is enabled by digital pathology and provides capabilities across the pharma value chain.
It will combine Agilent鈥檚 pharma partners network, expertise in companion diagnostic and immunohistochemistry (IHC) workflow, and Dako Omnis instrument install base with Akoya鈥檚 spatial analysis expertise, Clinical Laboratory Improvement Amendments (CLIA) lab capabilities and imagers install base.
Under a separate agreement, Akoya Biosciences will also be responsible for distributing and reselling Agilent鈥檚 Dako Omnis instrument as a part of the multiplex solution.
Akoya Biosciences CEO Brian McKelligon said: 鈥淢ultiplex tissue analysis has the potential to transform the field of cancer therapeutics and usher in a new era of precision pathology.
鈥淭his partnership and the combined strength of both organisations will catalyse the development and deployment of multiplex tissue-based biomarkers for the benefit of our biopharma and CRO partners and, ultimately, patients.鈥�
